jueves, 28 de febrero de 2019

Bispecific antibodies are next new thing in cancer immunotherapy - STAT

Bispecific antibodies are next new thing in cancer immunotherapy - STAT



STAT Plus: They’re the next new thing in cancer immunotherapy, but will bispecifics help more patients than CAR-Ts?

By SHARON BEGLEY


AMGEN
Though signs point to bispecifics, like other immunotherapies, eliminating cancer in a small fraction of people, there are hints they could help many more.

No hay comentarios:

Publicar un comentario